Skip to main content
. 2017 Dec 6;8(68):113090–113104. doi: 10.18632/oncotarget.23028

Figure 2. Glioma stem cell marker modulation after treatments.

Figure 2

FACS analysis for CD133 (A) and CD90 (B) markers in U251 and T98G cells after 48 h of treatment with 25 μM TMZ and/or of MET. Data were expressed as percentage of positive cells on the number of total cells. Data are shown are mean ± standard deviation. **p < 0.01; ***p < 0.001 vs control sample (untreated cells). #p < 0.05; ###p < 0.001 vs TMZ treatment.